A new FTC report found that pharmacy benefit managers have inflated the price of life-saving generic prescription drugs, ...

Tenax Therapeutics’ management will also participate in one-on-one investor meetings. To request a one-on-one meeting at the conference, please contact your Guggenheim representative. The live and ...

Ad hoc announcement pursuant to Art. 53 LR Full year Net sales grew +12% (cc1, +11% USD) with core operating income1 up +22% (cc, +19% USD) Sales growth driven by continued strong performance ...

Deliver returns: Continuing to embed operational excellence and deliver improved financials. Novartis remains disciplined and shareholder-focused in our approach to capital allocation, with ...

Inhibikase Therapeutics, Inc.’s IKT share price has surged by 18.23%, which has investors questioning if this is right time ...

Bezuclastinib plus sunitinib showed favorable safety and efficacy in GIST, outperforming sunitinib alone in phase 3 Peak ...

Treatment with bezuclastinib plus Sutent led to safe and efficacious outcomes versus Sutent treatment alone in gastrointestinal stromal tumors.

Shares of Tenax Therapeutics, Inc. (NASDAQ:TENX – Get Free Report) crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $4.54 and traded as ...

Chemotherapeutic agents are often used to treat cancer. They combat tumor growth, but also have a number of undesirable side ...

Tenax Therapeutics focuses on addressing cardiovascular and pulmonary diseases with high unmet medical needs. Besides ...

FTC stated that the 'Big 3' PBM organisations collectively generated over £5.94 billion ($7.3 billion) in revenue from 2017 to 2022.